Search results for "Erythema migrans"

showing 3 items of 3 documents

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

2017

Summary Background Lyme borreliosis develops in 1–5% of individuals bitten by ticks, but with a diagnostic gap affecting up to 30% of patients, a broadly applicable pharmacological prevention strategy is needed. Topical azithromycin effectively eradicated Borrelia burgdorferi sensu lato from the skin in preclinical studies. We assessed its efficacy in human beings. Methods In this randomised, double-blind, placebo-controlled, multicentre trial done in 28 study sites in Germany and Austria, adults were equally assigned to receive topical 10% azithromycin or placebo twice daily for 3 consecutive days, within 72 h of a tick bite being confirmed. Randomisation numbers, which were stratified by …

AdultMale0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationAzithromycinAzithromycinPlacebolaw.invention03 medical and health sciencesTicksDouble-Blind MethodRandomized controlled triallawGermanyInternal medicinemedicineClinical endpointAnimalsHumansTreatment FailureSeroconversioneducationLyme Diseaseeducation.field_of_studybusiness.industryAntibiotic ProphylaxisMiddle Agedbacterial infections and mycosesAnti-Bacterial AgentsSurgeryClinical trialInfectious DiseasesBorrelia burgdorferiErythema migransFemalebusinessmedicine.drugThe Lancet Infectious Diseases
researchProduct

Functional signs in patients consulting for presumed Lyme borreliosis

2019

Little is known about the functional symptoms associated with Lyme borreliosis (LB) in Europe. We aimed to assess functional symptoms associated with presumed LB and to compare patients with and without confirmed LB.We performed a retrospective monocenter study. Patients consulting for presumed LB were included.Between November 2015 and June 2018, 355patients were included (mean age: 51years, 52% of women) of which 48had LB: erythema migrans (42%), early disseminated LB (50%; 35% of neuroborreliosis cases), and late disseminated LB (8%). The most frequently reported functional symptoms were neuropathic pain (23%), arthralgia (23%), and asthenia (17%). Other functional symptoms were rare (≤1…

AdultMalemedicine.medical_specialtyFunctional symptomsDiagnosis Differential03 medical and health sciencesLyme diseasemedicineHumansLyme NeuroborreliosisLyme diseaseIn patientSerologic TestsReferral and ConsultationAgedRetrospective StudiesLyme borreliosis0303 health sciences030306 microbiologyLyme borreliosisbusiness.industryMean ageMiddle Agedmedicine.diseaseDermatology3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesTreatment OutcomeBorrelia burgdorferiNeuropathic painErythema migransErythema Chronicum MigransFemaleFranceSymptom AssessmentbusinessNeuroborreliosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Review of European and American guidelines for the diagnosis of Lyme borreliosis

2019

International audience; Lyme disease is a tick-borne bacterial disease with polymorphic clinical manifestations (cutaneous, rheumatological, and neurological). In recent years the issue of the diagnosis of this infection has been highly publicized on the Internet and other media in Europe and America. Some patients and physicians may share the perception that the diagnosis of the infection is not reliable in France. We reviewed current European and American guidelines on Lyme disease and performed a methodological evaluation of all guidelines. We retrieved 16 guidelines from seven countries. Our analysis revealed a global consensus regarding diagnosis at each stage of the infection. All gui…

medicine.medical_specialtyDiagnostic methodsRecommandationsGuidelinesSerologyDiagnosis Differential03 medical and health sciencesLyme disease[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesBorreliamedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyComputingMilieux_MISCELLANEOUSLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesBacterial diseasebiology030306 microbiologyLyme borreliosisbusiness.industryBorreliabiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyUnited States3. Good healthLYMEEuropeInfectious DiseasesFamily medicinePractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyLymeErythema migransbusinessMédecine et Maladies Infectieuses
researchProduct